Medicare Negotiations 2.0 Slash Prices Up To 85%, But Mean Cuts Barely Budge

 
• By Manas Mishra
  
The negotiations included Novo Nordisk's semaglutide, Merck's Janumet and AbbVie's Linzess. (Shutterstock)

More from Drug Pricing

More from Scrip